A meta-analysis from 2017 confirmed the safety of GLP-1 RAs for pancreatitis, reporting that the incidence of pancreatitis and pancreatic cancer was not significantly different between GLP-1 RAs and comparators (odds ratio (OR) 0.93; 95% CI 0.65–1.34; p = 0.71, and odds ratio 0.94; 95% CI 0.52–1.70; p = 0.84) [57]. This evidence concerns the gene GLP1R and pancreatic neoplasm.